^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

CD22low/Bcl-2high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia

Published date:
11/04/2021
Excerpt:
Inotuzumab ozogamicin (InO)...In order to identify better predictors of response to InO, we analyzed 68 samples from 28 patients with multiply R/R ALL enrolled in Children’s Oncology Group trial AALL1621 (NCT02981628)...CD22high expression predicting good response to InO versus CD22low/Bcl-2high expression predicting poor response.
DOI:
10.1182/blood-2021-149037
Trial ID: